Carisma Therapeutics Inc Stock Price, News & Analysis

Welcome to our dedicated page for Carisma Therapeutics news (Ticker: CARM), a resource for investors and traders seeking the latest updates and insights on Carisma Therapeutics stock.

Carisma Therapeutics Inc. (CARM) generates news primarily as a clinical-stage biopharmaceutical company that has focused on engineered macrophage and monocyte immunotherapies and, more recently, on corporate restructuring and wind down activities. News coverage of CARM reflects both its scientific developments and its significant corporate and listing transitions.

On the scientific side, Carisma has issued press releases on preclinical and clinical milestones across oncology and fibrosis. These include data on CT-0525, an ex vivo CAR-monocyte therapy for HER2-overexpressing solid tumors, CT-1119 for mesothelin-positive tumors, and engineered macrophage programs for liver fibrosis. The company has also reported preclinical results from its anti-GPC3 in vivo CAR-M program for hepatocellular carcinoma, developed in collaboration with Moderna, highlighting tumor-targeting activity and off-the-shelf potential.

Carisma news has also covered conference participation, with company representatives presenting at events such as the Society for Immunotherapy of Cancer (SITC), the American Association for the Study of Liver Diseases (AASLD) Liver Meeting, and healthcare investor conferences hosted by firms like Oppenheimer, Evercore ISI, and H.C. Wainwright. These announcements often summarize new data, poster presentations, and updates on the company’s pipeline strategy.

More recent news has focused on strategic alternatives, restructuring, and listing status. Carisma has announced workforce reductions, the pausing or discontinuation of certain programs, and a revised operating plan centered on evaluating strategic options and preserving capital. Additional releases have detailed the company’s noncompliance with Nasdaq listing requirements, the suspension of trading on Nasdaq, the commencement of trading on the OTCID market tier, and the Board’s decision to voluntarily delist and deregister its common stock as part of an orderly wind down of operations.

Investors and observers following the CARM news feed can review this sequence of scientific, strategic, and regulatory announcements to understand how Carisma’s macrophage engineering platform evolved, how its collaboration with Moderna changed over time, and how the company moved from active development to asset monetization and wind down planning.